PAVM•PAVmed reported a preliminary third-quarter 2026 net loss attributable to common stockholders of $11.75 million, up 86% year over year, while revenue rose to $41,000. Operating expenses increased 40% to $6.77 million.
PAVmed's preliminary third-quarter 2026 net loss attributable to common stockholders widened 86% year over year to $11.75 million. Revenue rose to $41,000, and operating expenses climbed 40% to $6.77 million. Lucid Diagnostics began receiving Medicare payments for EsoGuard in October, and Veris Health completed an implantable monitor design freeze and began animal testing, targeting an early 2027 FDA submission.
